Corcept Therapeutics Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CORT research report →
Range $50 – $165
Price Chart
About the company
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable.
- CEO
- Joseph K. Belanoff
- IPO
- 2004
- Employees
- 730
- HQ
- Redwood City, CA, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a longer-term corrective phase after trading well below its 200-day average, with the 50-day also beneath the 200-day. That keeps the regime weak despite a rebound from the 52-week low and a wide gap below the 52-week high, so shareholders should watch for a sustained trend repair.
Street sentiment is constructive, with a Buy consensus and a $132.8 median target versus a $68.33 share price. Recent action is mixed but still supportive: several firms lifted targets into the $150-$165 range, while Wolfe cut to Underperform and the target spread remains wide at $50 to $165.
Earnings momentum has improved, with the last two quarters beating estimates by 48.5% and 1000.0% after a weaker stretch earlier in the year. Next-year EPS is modeled at 4.9833 versus 1.33 TTM, so the setup favors execution on relacorilant progress and continued margin discipline.
Recent insider activity leans to net selling, led by director James N. Wilson and director Daniel N. Swisher Jr. The M-exempt entries tied to Swisher and Sean Maduck look like routine award or vesting activity, but the repeated open-market sales point to some profit-taking rather than accumulation.
Profitability is solid, with a 98.5% gross margin, 11.51% operating margin, and 16.84% net margin. Growth is strong too, with revenue up 64% year over year and earnings up 531.3%, while the balance sheet stays clean with $372.2 million in cash against just $6.1 million of debt.
Corcept screens as a premium biotech name, supported by high gross margins and a cash-rich balance sheet rather than leverage or scale. The valuation is demanding versus peers at 195.23x earnings, so the market is paying for pipeline and earnings expansion rather than current profitability alone.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.96B
- P/E
- 42.61
- Fwd P/E
- 28.13
- PEG
- 0.85
- P/S
- 7.26
- P/B
- 8.17
- EV/EBITDA
- 51.38
- Div Yield
- 0.00%
- Gross Margin
- 98.54%
- Op Margin
- 11.51%
- Net Margin
- 16.81%
- ROE
- 22.94%
- ROIC
- 12.92%
Latest fiscal year · YoY change
- Revenue
- $761.41M+12.8%
- Gross Profit
- $748.43M+12.7%
- Op Income
- $44.80M
- Net Income
- $99.65M-28.7%
- EPS
- $0.95-29.6%
- OCF Growth
- -28.3%
- FCF Growth
- -27.6%
- 52W High
- $126.38
- 52W Low
- $28.66
- 50D MA
- $100.01
- 200D MA
- $77.05
- Beta
- 0.45
- RSI (14)
- 21
- Avg Volume
- 1.26M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Corcept posted record Q3 revenue and profit, kept 2026 revenue guidance unchanged, and said both its Cushing's and ovarian cancer franchises are still early in their growth curves.· November 3, 2026
- Q3 2026 revenue was $340.5 million, up 33% sequentially and 64% year over year.
- Net income rose to $126.8 million versus $43 million in Q2 and $19.7 million a year ago.
- Korlym and authorized generic revenue was $249.1 million; Lifyorli revenue was $91.4 million and management said launch demand remains strong.
- The company reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
- Management highlighted expanding awareness of hypercortisolism, a December 17 PDUFA date for relacorilant, and multiple pipeline readouts expected by end of next year.
Corcept reported third-quarter 2026 revenue of $340.5 million, a 33% increase from the second quarter and a 64% increase versus the prior year period. Korlym and authorized generic revenue was $249.1 million, while Lifyorli revenue was $91.4 million, up 92% from the prior quarter. Net income was $126.8 million compared with $43 million in Q2 and $19.7 million in the prior-year period. Cash and investments were $662 million at September 30, up $118 million in the quarter, and the company repurchased $44 million of common stock in Q3. Management reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion.
CEO Joseph Belanoff framed the quarter as validation of Corcept's GR antagonism platform across endocrinology, oncology, and future indications. He said hypercortisolism is increasingly recognized as underdiagnosed, that the ADA's screening recommendation should expand diagnosis, and that relacorilant could accelerate growth if approved by the December 17 PDUFA date. He was upbeat about BELLA data and said the company expects to move earlier in ovarian cancer and eventually into other cancers and diseases.
CFO Atabak Mokari led with the hard numbers: $340.5 million in Q3 revenue, $126.8 million in net income, $662 million in cash and investments, and $44 million of share repurchases. He said the company is reiterating the $1.1 billion to $1.2 billion revenue outlook because management's midpoint remains its best estimate given many probabilistic drivers, and noted the range has already been raised several times this year. He did not introduce new margin guidance, but the quarter's revenue and earnings strength implied continued operating leverage.
Analysts pressed on why guidance was unchanged despite strong Lifyorli and Korlym performance; management said the midpoint of the range remains its best thinking and that the company has already raised guidance multiple times this year. Questions also focused on Lifyorli's long-term positioning versus new ovarian cancer drugs and whether combinations with ADCs could emerge; management said the drug's differentiated mechanism and combination potential should preserve its role, including with chemo, ADCs, and immunotherapy. On relacorilant, management said the FDA only asked for a specific global statistical test after the prior CRL and that they cannot discuss the review further ahead of the December 17 decision. On MASH, management clarified the fibrosis improvement was absolute, not placebo-adjusted, and explained the shift to a 100 mg daily/intermittent regimen as a way to optimize efficacy while limiting ALT rises.
The bullish case from the call is that both commercial franchises are gaining momentum: Lifyorli is seeing strong demand, broader physician adoption, repeat prescribing, and use earlier in therapy, while Korlym continues to grow and relacorilant could expand the Cushing's market further if approved. Management also pointed to external validation from the ADA/AACE and to multiple pipeline catalysts in oncology, MASH, and ALS over the next year.
The main risks are that guidance was not raised despite a strong quarter, suggesting management is still leaving room for volatility or conservatism in the back half. Relacorilant still faces a key regulatory decision on December 17, and management would not discuss FDA feedback beyond the resubmitted NDA process. In oncology, management acknowledged that new ovarian cancer drugs are emerging and that Lifyorli's longer-term role will depend on data, combinations, and continued adoption into earlier lines of therapy.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.6%
- Shares Outstanding
- 109.44M
- Float Shares
- 96.97M
of shares held by institutions
451 13F filers
Buy/sell ratio 0.38. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.20M | ▼ 2.24M |
| Vanguard Group Inc | 9.49M | ▼ 42.25K |
| Ingalls & Snyder LLC | 7.67M | ▼ 266.71K |
| Renaissance Technologies LLC | 4.85M | ▼ 411.55K |
| Vanguard Portfolio Management LLC | 4.78M | ▼ 267.57K |
| Vanguard Capital Management LLC | 4.35M | ▲ 180.92K |
| Parallel Advisors, LLC | 3.90M | ▼ 59.63K |
| Fmr LLC | 3.49M | ▲ 151.10K |
| State Street Corp | 3.10M | ▼ 174.42K |
| Aqr Capital Management LLC | 2.58M | ▲ 2.18M |
| Geode Capital Management, LLC | 2.34M | ▼ 196.83K |
| Tang Capital Management LLC | 1.50M | 0 |
Held by 528 ETFs
Biggest fund positions in CORT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | WILSON JAMES N | sell | 2,191 |
| Nov 13, 26 | WILSON JAMES N | sell | 7,221 |
| Nov 13, 26 | WILSON JAMES N | sell | 563 |
| Nov 13, 26 | WILSON JAMES N | sell | 25 |
| Nov 10, 26 | Swisher Daniel N JR | other | 400 |
| Nov 10, 26 | Swisher Daniel N JR | other | 400 |
| Nov 10, 26 | Swisher Daniel N JR | other | 1,100 |
| Nov 10, 26 | Swisher Daniel N JR | sell | 1,500 |
| Nov 10, 26 | Swisher Daniel N JR | other | 1,100 |
| Nov 2, 26 | Maduck Sean | other | 11,841 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CORT coverage
Recent articles, reports, and earnings notes.

Corcept Therapeutics (CORT): Lifyorli Launch Drives Growth
Corcept is evolving from a single-product endocrinology story into a two-franchise biopharma company, with Lifyorli adding a new growth engine. The stock looks fairly valued after strong Q2 revenue growth, but execution risk and a young launch keep the rating at Hold.

Corcept Therapeutics (CORT): Growth Upside vs. Rich Valuation
Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.

Corcept Therapeutics Incorporated (CORT) jumps 19.5%
Corcept Therapeutics Incorporated (CORT) jumps after hours as investors react to its Q2 2026 earnings event and a fresh price-target hike from Canaccord Genuity. The stock moved sharply above its prior 52-week high, but valuation remains stretched and analyst views are sharply divided.
Want a deeper read on CORT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Corcept Therapeutics: Two Franchises, But One Broader Cortisol Opportunity
seekingalpha.com · Nov 20
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
gurufocus.com · Nov 16
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
businesswire.com · Nov 16
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Now Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net · Nov 7
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
zacks.com · Nov 4
Corcept Therapeutics Incorporated (CORT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Corcept Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 18, 2026 · Live quote · Not investment advice